Tag: MRSA

Altered quorum sensing and physiology of Staphylococcus aureus during spaceflight detected by multi-omics data analysis

CDC. (ed CDC) (U.S. Department of Health and Human Services, CDC; 2019, Atlanta, GA, 2019). Krismer, B., Weidenmaier, C., Zipperer, A. & Peschel, A. The commensal lifestyle of Staphylococcus aureus and its interactions with the nasal microbiota. Nat. Rev. Microbiol. 15, 675–687 (2017). Article  CAS  PubMed  Google Scholar  Somerville, G….

Continue Reading Altered quorum sensing and physiology of Staphylococcus aureus during spaceflight detected by multi-omics data analysis

Seroprevalence and Molecular Characterization of B. abortus

Introduction Brucellosis is a zoonotic disease caused by Brucella spp., a gram-negative facultative intracellular coccobacillus.1 These microorganisms can infect livestock, wildlife, and humans, causing significant public concern and substantial agricultural economic loss. Currently, at least six novel Brucella species have been identified: Brucella pinnipedialis, Brucella ceti,2 Brucella papionis,3 Brucella microti,4…

Continue Reading Seroprevalence and Molecular Characterization of B. abortus

SPADes Tool

Forum:SPADes Tool 0 0 Entering edit mode 2 hours ago hafizshaheerahmad006 • 0 why should I chose SPADes assembler tool over the Velvet and other for MRSA genomic study Bioinformatics Assembler MRSA SPADes • 14 views ADD COMMENT • link 2 hours ago by hafizshaheerahmad006 • 0 Login before adding…

Continue Reading SPADes Tool

Holiday Merriment and Sharing the Microbiome

Kirsten D/peopleimages.com/Adobe Stock The holidays are upon us, with many opportunities to visit with extended family members, renew old friendships, and spread cheer to neighbors and workmates. It is a wonderful time of year for human gatherings, providing a chance to share updated activities from the past year, exchange ideas,…

Continue Reading Holiday Merriment and Sharing the Microbiome

Are there any primers that are specifically designed for the molecular identification of Fusarium species?

Which region of the rRNA is used for synethsizing primers for species identification?5 answersThe region of the rRNA used for synthesizing primers for species identification is the mitochondrial 12S rRNA gene. This gene segment is commonly targeted in PCR-based methods for species identification and taxonomic classification. It has been used…

Continue Reading Are there any primers that are specifically designed for the molecular identification of Fusarium species?

SSR molecular marker developments and genetic diversity analysis of Zanthoxylum nitidum (Roxb.) DC

Commission, S. P. Pharmacopoeia of the People’s Republic of China (Pharmacopoeia of the People’s Republic of China, 2020). Google Scholar  Sun, X. & Sun, F. Shennong Materia Medica Classic (People’s Health Publishing House, 1963). Google Scholar  Huang, C. Flora of China Vol. 43 (Science Press, 1997). Google Scholar  Hu, J….

Continue Reading SSR molecular marker developments and genetic diversity analysis of Zanthoxylum nitidum (Roxb.) DC

Known mechanisms cannot account for a third of reduced susceptibility in non-aureus staphylococci

Our NAS collection comprised over 30 species of Staphyloccocus, including at least 10 isolates of S. epidermidis, S. capitis, S. haemolyticus, S. hominis, S. saprophyticus, S. simulans and S. warneri (Table 1). Isolates were collected over a 4-year period from 2013 to 2016. Table 1 Frequency of non-aureus staphylococcal speciesa…

Continue Reading Known mechanisms cannot account for a third of reduced susceptibility in non-aureus staphylococci

RPA biosensors for rapid zoonoses screening

Introduction Since the emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 2019, this coronavirus has spread to more than 200 countries, cumulatively infecting 672 million people and causing 6.84 million deaths. Moreover, the emergence of numerous variant strains (α, β, γ, δ, and Omicron) presents a serious challenge for…

Continue Reading RPA biosensors for rapid zoonoses screening

Diagnostic and commensal Staphylococcus pseudintermedius genomes reveal niche adaptation through parallel selection of defense mechanisms

Bond, R. & Loeffler, A. What’s happened to Staphylococcus intermedius? Taxonomic revision and emergence of multi-drug resistance. J. Small Anim. Pr. 53, 147–154 (2012). Article  CAS  Google Scholar  Carroll, K. C., Burnham, C. D. & Westblade, L. F. From canines to humans: clinical importance of Staphylococcus pseudintermedius. PLoS Pathog. 17,…

Continue Reading Diagnostic and commensal Staphylococcus pseudintermedius genomes reveal niche adaptation through parallel selection of defense mechanisms

DNA Diagnostics Market for Non-Invasive Cancer Detection is poised to reach a projected US$ 51.5 Billion by 2032, according to FMI

The healthcare and genetics industries have seen a major shift because to the DNA diagnostics market, which has completely changed how we identify, treat, and comprehend a wide range of illnesses and ailments. With the development of technology and our understanding of genetics, this quickly expanding industry has expanded to…

Continue Reading DNA Diagnostics Market for Non-Invasive Cancer Detection is poised to reach a projected US$ 51.5 Billion by 2032, according to FMI

Ceftobiprole NDA Accepted for 3 Severe Infection Indications

What You Should Know The FDA’s acceptance of the New Drug Application (NDA) for ceftobiprole, submitted in August, could signifies a significant step forward in addressing severe bacterial infections. Ceftobiprole was designated as a candidate for the US Generate Antibiotics Incentives Now (GAIN) Act, which facilitates the development of new…

Continue Reading Ceftobiprole NDA Accepted for 3 Severe Infection Indications

Unraveling the secrets of the prevalent Staphylococcus strain

In a recent study published in Microbial Genomics, researchers investigated the genomes of a group of Staphylococcus capitis isolates from neonates. Study: Characterisation of neonatal Staphylococcus capitis NRCS-A isolates compared with non NRCS-A Staphylococcus capitis from neonates and adults. Image Credit: Dmitry Kalinovsky/Shutterstock.com Background NRCS-A, a clone of S. capitis,…

Continue Reading Unraveling the secrets of the prevalent Staphylococcus strain

IV Antibiotic Ceftobiprole Under Review for Serious Bacterial Infections

The Food and Drug Administration (FDA) has accepted the New Drug Application for ceftobiprole, an investigational, broad spectrum cephalosporin antibiotic for intravenous administration. Basilea is seeking approval for 3 indications: Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia…

Continue Reading IV Antibiotic Ceftobiprole Under Review for Serious Bacterial Infections

Basilea announces FDA acceptance of New Drug Application

Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP) Prescription Drug User Fee Act (PDUFA) goal date set for April 03, 2024 Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, October 02, 2023 Basilea Pharmaceutica Ltd, Allschwil…

Continue Reading Basilea announces FDA acceptance of New Drug Application

Secondary infection surveillance | IDR

Introduction The coronavirus disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continues to threaten human life worldwide. The disease severity of COVID-19 patients is very wide: from an asymptomatic carrier state to severe infection and critical illness with intensive care admission and/or mechanical…

Continue Reading Secondary infection surveillance | IDR

Basilea announces New England Journal of Medicine

Allschwil, Switzerland, September 28, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine (NEJM), one…

Continue Reading Basilea announces New England Journal of Medicine

Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Allschwil, Switzerland, September 28, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that data from the successful phase 3 study ERADICATE were published in the New England Journal of Medicine (NEJM), one…

Continue Reading Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia

Interim results for the six months ended 30 June 2023

Destiny Pharma plc (“Destiny Pharma” or the “Company”)   Interim results for the six months ended 30 June 2023   Active discussions with potential partners for XF-73 nasal supported by new market analysis that underscores $2bn market opportunity   Partnering deal with Sebela Pharmaceuticals for NTCD-M3 in North America fully…

Continue Reading Interim results for the six months ended 30 June 2023

Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit

Guh, A. Y. et al. Trends in U.S. Burden of Clostridioides difficile infection and outcomes. N. Engl. J. Med. 382, 1320–1330 (2020). Article  CAS  PubMed  PubMed Central  Google Scholar  Antibiotic Resistance Threats in the United States (Centers for Disease Control and Prevention, 2019); doi.org/10.15620/cdc:82532 Evans, C. T. & Safdar, N….

Continue Reading Longitudinal genomic surveillance of carriage and transmission of Clostridioides difficile in an intensive care unit

Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

The present protocol prepares and evaluates the physical properties, immune response, and in vivo protective effect of a novel nanoemulsion adjuvant vaccine. The demonstrated protocol underlined the direct and effective experimental approach and the detailed steps to immune response effects of novel viral adjuvants. This protocol provides the research with…

Continue Reading Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

One-tube RPA-CRISPR Cas12a/Cas13a rapid detection of methicillin-resistant Staphylococcus aureus,Analytica Chimica Acta

At present, methicillin-resistant Staphylococcus aureus (MRSA) has caused a serious impact on a global scale. The infection and carrier rate of MRSA in the community is increasing year by year, but there is still no convenient detection system for on-site rapid detection. It is very important to select a rapid…

Continue Reading One-tube RPA-CRISPR Cas12a/Cas13a rapid detection of methicillin-resistant Staphylococcus aureus,Analytica Chimica Acta

Social demographics determinants for resistome and microbiome variation of a multiethnic community in Southern Malaysia

Dadgostar, P. Antimicrobial resistance: Implications and costs. Infect. Drug Resistance 12, 3903–3910 (2019). Article  CAS  Google Scholar  Rosenblatt-Farrell, N. The landscape of antibiotic resistance. Environ. Health Perspect. 117, A244–A250 (2009). Article  PubMed  PubMed Central  Google Scholar  Roberts, S. C. & Zembower, T. R. Global increases in antibiotic consumption: a concerning…

Continue Reading Social demographics determinants for resistome and microbiome variation of a multiethnic community in Southern Malaysia

Machine learning and metagenomics reveal shared antimicrobial resistance profiles across multiple chicken farms and abattoirs in China

Wu, Z. Antibiotic Use and Antibiotic Resistance in Food-Producing Animals in China OECD Food, Agriculture and Fisheries Paper No. 134 (OECD, 2019); doi.org/10.1787/4adba8c1-en Looft, T. et al. In-feed antibiotic effects on the swine intestinal microbiome. Proc. Natl Acad. Sci. USA 109, 1691–1696 (2012). Article  ADS  CAS  PubMed  PubMed Central  Google…

Continue Reading Machine learning and metagenomics reveal shared antimicrobial resistance profiles across multiple chicken farms and abattoirs in China

Microorganisms | Free Full-Text | Whole Genome Sequencing and Molecular Epidemiology of Clinical Isolates of Staphylococcus aureus from Algeria

1. Introduction S. aureus is the leading cause of nosocomial infections worldwide [1]. Although it is a normal resident of the skin and mucous membranes of humans and animals, S. aureus can become an opportunistic pathogen by deploying a plethora of virulence factors to cause a variety of infections, ranging…

Continue Reading Microorganisms | Free Full-Text | Whole Genome Sequencing and Molecular Epidemiology of Clinical Isolates of Staphylococcus aureus from Algeria

Real-Time Pcr (Qpcr), Endpoint Pcr, And Dpcr Market Trends, Growth, & Share-2031

(MENAFN– Straits Research) Real-time PCR, or quantitative PCR, is an established method for sensitive and rapid nucleic acid quantification in various biological samples. Real-time PCR, or quantitative PCR, is an established method for sensitive and rapid nucleic acid quantification in various biological samples. Endpoint PCR, also known as conventional PCR,…

Continue Reading Real-Time Pcr (Qpcr), Endpoint Pcr, And Dpcr Market Trends, Growth, & Share-2031

Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP) NDA eligible for Priority Review Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 04, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical…

Continue Reading Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole

Basilea Seeks Approval of Intravenous Antibiotic Ceftobiprole

The New Drug Application (NDA) for ceftobiprole medocaril (ceftobiprole) has been submitted for review to the Food and Drug Administration (FDA) by Basilea. Ceftobiprole is a cephalosporin antibiotic for intravenous administration with rapid bactericidal activity against a wide range of Gram positive bacteria such as Staphylococcus aureus, including methicillin-resistant strains…

Continue Reading Basilea Seeks Approval of Intravenous Antibiotic Ceftobiprole

Microorganisms | Free Full-Text | Whole-Genome Sequencing-Based Screening of MRSA in Patients and Healthcare Workers in Public Hospitals in Benin

1. Introduction Staphylococcus aureus is an important pathogen in healthcare and community settings that can cause a broad spectrum of diseases, ranging from skin and soft-tissue infections to invasive diseases such as pneumonia, septicemia, and endocarditis [1]. In the 1960s [2], soon after the introduction of methicillin into the healthcare…

Continue Reading Microorganisms | Free Full-Text | Whole-Genome Sequencing-Based Screening of MRSA in Patients and Healthcare Workers in Public Hospitals in Benin

CPA-Cas12a-based lateral flow strip for portable assay of Methicillin-resistant Staphylococcus aureus in clinical sample | Journal of Nanobiotechnology

Principle of CPA-Cas 12a lateral flow assay strategy CPA and CPA-Cas 12a sensing strategies were proposed for detection of nuc and mecA genes in MRSA respectively. According to the sequence of the target gene, we designed two PAM sites and four pairs of primer according to the principles of double-crossing…

Continue Reading CPA-Cas12a-based lateral flow strip for portable assay of Methicillin-resistant Staphylococcus aureus in clinical sample | Journal of Nanobiotechnology

Development of an inducible Cas9 nickase and PAM-free Cas12a platform for bacterial diagnostics

. 2023 Jul 11;265:124931. doi: 10.1016/j.talanta.2023.124931. Online ahead of print. Affiliations Expand Affiliations 1 State Key Laboratory of Marine Resource Utilization in South China Sea, Marine College, Hainan University, Haikou 570228, China. 2 Agriculture and Agri-Food Canada, Fredericton, New Brunswick, E3B 4Z7, Canada; Nutra Health Products and Technologies Inc., Fredericton…

Continue Reading Development of an inducible Cas9 nickase and PAM-free Cas12a platform for bacterial diagnostics

Aridis Receives Agreement from the European Medicines

LOS GATOS, Calif., July 17, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the European Medicines Agency (EMA) on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with…

Continue Reading Aridis Receives Agreement from the European Medicines

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro

The protocols provide a method to examine the antimicrobial activities of nanoparticle and nanostructured surfaces from preliminary stage investigations to more complex surface examinations. Unlike previously described methods that resulted in incomparable data across studies, these methods produce consistent and comparable results across different nanoparticle materials, nanostructured materials, and microbial…

Continue Reading Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro

Advances in DNA Sequencing Technology to Drive Molecular Diagnostics Market Growth

Molecular Diagnostics Market The global Molecular Diagnostics Market Size was valued at US$ 38 Billion in 2022 and is projected to reach US$ 59.4Billion by 2033, at a CAGR of 4.3%. The global molecular diagnostics market has been experiencing significant growth in recent years. Factors driving market growth include the…

Continue Reading Advances in DNA Sequencing Technology to Drive Molecular Diagnostics Market Growth

NIAID Funding Available for Development of Anti-Infective Strategies Against Viral, Bacterial, and Fungal Pathogens and their Toxins

By Laura Powell, Managing Consultant and Steve Morris, Managing Director CHARLESTON, S.C., June 28, 2023 /PRNewswire/ — The National Institute of Allergy and Infectious Diseases (NIAID) recently released a Notice of Special Interest (NOSI) aimed at encouraging research proposals on targeted protein and nonprotein degradation for the development of anti-infective…

Continue Reading NIAID Funding Available for Development of Anti-Infective Strategies Against Viral, Bacterial, and Fungal Pathogens and their Toxins

Non disseminative nano-strategy against in vivo Staphylococcus aureus biofilms

Materials The lipid cetyl palmitate was a kind gift from Gattefossé (Gattefossé SAS, Saint-Priest, France). DSPE-PEG2000-NH2 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (ammonium salt)) was purchased from Avanti Polar Lipids Inc. (Alabaster, Alabama, USA). D-Phenylalanine, D-Proline, D-Tyrosine, triethylamine (TEA), dicyclohexylcarbodiimide (DCC), N-hydroxysuccinimide (NHS), sodium hydroxide (NaOH), sodium chloride, moxifloxacin hydrochloride (MOX), farnesol 95%, Tween®80,…

Continue Reading Non disseminative nano-strategy against in vivo Staphylococcus aureus biofilms

Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

LOS GATOS, Calif., June 08, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its first quarter ended March 31, 2023. First Quarter & Subsequent Highlights Met…

Continue Reading Aridis Pharmaceuticals Announces First Quarter 2023 Financial Results and Business Update

Next-Generation Sequencing (NGS)- Definition, Types, Applications, Limitations

What is Next-Generation Sequencing (NGS)? Next-Generation Sequencing (NGS), also known as high-throughput sequencing, has revolutionized the field of genomics and molecular biology by allowing the sequencing of thousands to millions of DNA molecules simultaneously. It encompasses a range of different sequencing technologies, all aimed at producing large amounts of sequence…

Continue Reading Next-Generation Sequencing (NGS)- Definition, Types, Applications, Limitations

Vancomycin intermediate-resistant Staphylococcus haemolyticu | IDR

Wanyang Dong,1,* Qi Peng,1,* Xiaohua Tang,1,2,* Tian Zhong,1 Shunan Lin,1 Ziling Zhi,1 Jingyi Ye,1 Bixia Yang,1 Ning Sun,1,3 Wenchang Yuan1 1Guangzhou Key Laboratory for Clinical Rapid Diagnosis and Early Warning of Infectious Diseases, KingMed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, 510180, People’s Republic of China; 2Third Affiliated Hospital…

Continue Reading Vancomycin intermediate-resistant Staphylococcus haemolyticu | IDR

Efficient machine learning pipeline predicts the location of nanoscale interactions

Identifying whether and how a nanoparticle and protein will bind with one another is an important step toward being able to design antibiotics and antivirals on demand, and a computer model developed at the University of Michigan can do it. The new tool could help find ways to stop antibiotic-resistant…

Continue Reading Efficient machine learning pipeline predicts the location of nanoscale interactions

Nanobiotics: AI for discovering where and how nanoparticles bind with proteins

The new computer model, NeCLAS, predicts that a nanoparticle, shown as a set of yellow balls attached by netting, fits neatly around a very specific protrusion on a protein, marked in blue. The binding site is confirmed by experiments. These kinds of nanoparticles, called molecular tweezers, can be used to…

Continue Reading Nanobiotics: AI for discovering where and how nanoparticles bind with proteins

2023-05-31 | NDAQ:ARDS | Press Release

LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care…

Continue Reading 2023-05-31 | NDAQ:ARDS | Press Release

Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

LOS GATOS, Calif., May 31, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced positive feedback from the FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care…

Continue Reading Aridis Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

A Research Study on the Antimicrobial Properties of Cannabis

Inexpensive in vitro Methods to Evaluate the Impact of Cannabinoid-containing Products on Sentinel Lactobacillus spp.  S. Lewin 1, A. Hilyard2, H. Piscatelli1, A. Hangman1, D. Petrik1, P. Miles2, and C. Orser2 1MatMaCorp Inc, Lincoln NE; 2Apothercare LLC, Boston MA  Abstract The public has readily embraced cannabidiol (CBD) in countless unregulated products…

Continue Reading A Research Study on the Antimicrobial Properties of Cannabis

Point-of-care Molecular Diagnostics Market is rising to US$ 11.1 billion by 2033 is estimated at a CAGR of 9.7%

The Point-Of-Care Molecular Diagnostics Market is predicted to secure a valuation of US$ 4.4 billion in 2023 and is rising to US$ 11.1 billion by 2033. The market is estimated at a CAGR of 9.7% during the forecast period. Rising infectious and chronic diseases, such as cardiovascular, diabetes, and COVID-19, are increasing…

Continue Reading Point-of-care Molecular Diagnostics Market is rising to US$ 11.1 billion by 2033 is estimated at a CAGR of 9.7%

Pathogen Diagnosis Value of Nanopore Sequencing

Introduction Severe hospital-acquired pneumonia (SHAP) is the most common acquired infection in the intensive care unit (ICU) and one of the main causes of increased mortality in ICU patients.1,2 Potential multidrug-resistant pathogens are very common in ICU-acquired pneumonia, including Pseudomonas aeruginosa, Acinetobacter spp., methicillin-resistant Staphylococcus aureus (MRSA), and ultrabroad spectrum…

Continue Reading Pathogen Diagnosis Value of Nanopore Sequencing

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited

NEW YORK – Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (‘Aptorum Group‘ or ‘Company’), today announced that its wholly owned subsidiary Aptorum Therapeutics Limited (‘ATL’) has entered into a non-binding Letter of Intent and Term Sheet to merge its 100% subsidiary, Paths Innovation Limited and its underlying business with…

Continue Reading Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited

NEW YORK & LONDON & PARIS, May 01, 2023–(BUSINESS WIRE)–Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that its wholly owned subsidiary Aptorum Therapeutics Limited (“ATL”) has entered into a non-binding Letter of Intent and Term Sheet (“Term Sheet”) to merge (“Transaction”)…

Continue Reading Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited

Research by Paradise Valley resident featured at SOURCE in NYC

Iya Agha from Paradise Valley was among the New York Institute of Technology students who showcased their scholarly work at the annual Symposium of University Research and Creative Expression on April 14. At the institute’s New York City campus, 119 student research projects were shared in the form of oral…

Continue Reading Research by Paradise Valley resident featured at SOURCE in NYC

5 biotech companies to discover in Bangalore

Bangalore, also known as Bengaluru, is widely recognized as India’s leading biotech hub, with some of the largest biotech companies in the country based in the city. In this article, we take a look at five biotechs to come out of Bangalore.  Home to the Centre for Cellular and Molecular…

Continue Reading 5 biotech companies to discover in Bangalore

Celebrating 20 Years of SOURCE | News

Pictured: Students Emaan Naeem Mughal, left, and Puneet Dhaliwal present their academic research poster, “The Effect of Brain Dehydration on the Efficacy of Cerebrospinal Fluid’s Cushioning Effect: A Computational Study.” One hundred twenty three abstracts were accepted for oral or poster presentations at this year’s Symposium of University Research and…

Continue Reading Celebrating 20 Years of SOURCE | News

Molecular Epidemiology and Characterization of Multidrug-Resistant MRS

Introduction Increasing antibiotic resistance is a worrisome trend being observed worldwide. Methicillin-resistant Staphylococcus aureus (MRSA) was first reported in the United Kingdom (UK) in 1961 and has since been reported throughout the world as a nosocomial pathogen.1 A steady increase in the occurrence of MRSA strains has been reported in…

Continue Reading Molecular Epidemiology and Characterization of Multidrug-Resistant MRS

Does higher caffeine and coffee intake impact colonic microbiota composition and diversity?

​​​​​​​In a recent study published in the Nutrients journal, researchers in the United States investigated the association between caffeine, coffee consumption, and the colonic microbiome. ​​​​​​​ Study: The Association between Caffeine Intake and the Colonic Mucosa-Associated Gut Microbiota in Humans—A Preliminary Investigation. Image Credit:Rawpixel.com/Shutterstock.com Background Caffeine has been extensively consumed in…

Continue Reading Does higher caffeine and coffee intake impact colonic microbiota composition and diversity?

a solution for antimicrobial resistance?

The discovery of penicillin in 1928 by Alexander Fleming was a momentous moment in the world of healthcare, eventually leading to the development of antibiotic drugs that allowed physicians to treat illnesses and infections that were once severe and life-threatening. But our reliance on antibiotics has now led to an…

Continue Reading a solution for antimicrobial resistance?

Advance on engineering of bacteriophages

Introduction Bacteriophage (phage) is a class of widespread viruses exclusively infecting bacteria, playing a key role in ecosystems.1–3 Since phages were discovered over a hundred years ago, many techniques and reagents, such as DNA polymerase, restriction endonuclease, ligase, and CRISPR/Cas system, have been developed from phages, which have together accelerated…

Continue Reading Advance on engineering of bacteriophages

Mining metagenomes reveals diverse antibiotic biosynthetic genes in uncultured microbial communities

World Health Organization (2020) Lack of new antibiotics threatens global efforts to contain drug-resistant infections. World Health Organization, New release Geneva Google Scholar  Kmietowicz Z (2017) Few novel antibiotics in the pipeline, WHO warns. BMJ: British Medical Journal (Online) 358:1. doi.org/10.1136/bmj.j4339 Article  Google Scholar  Falagas ME, Lourida P, Poulikakos P,…

Continue Reading Mining metagenomes reveals diverse antibiotic biosynthetic genes in uncultured microbial communities

New Arylazo-Based (Chromene-Thiazole) Hybrids as Potential MRSA Inhibitors

A three-component protocol was established to efficiently synthesize (chromene-thiazole) and related arylazo analogs in good to excellent yields. The desired products were prepared by reacting the appropriate salicylaldehydes, 2-cyanothioacetamide, and chloroacetone or hydrazonyl chlorides. Using piperidine as a mediator in ethanol at 80 °C for 4-6 h, the three-component protocol…

Continue Reading New Arylazo-Based (Chromene-Thiazole) Hybrids as Potential MRSA Inhibitors

Cas12a/Guide RNA-Based Platforms for Rapidly and Accurately Identifying Staphylococcus aureus and Methicillin-Resistant S. aureus

In order to ensure the prevention and control of methicillin-resistant Staphylococcus aureus (MRSA) infection, rapid and accurate detection of pathogens and their resistance phenotypes is a must. Therefore, this study aimed to develop a fast and precise nucleic acid detection platform for identifying S. aureus and MRSA. We initially constructed…

Continue Reading Cas12a/Guide RNA-Based Platforms for Rapidly and Accurately Identifying Staphylococcus aureus and Methicillin-Resistant S. aureus

Natural killer cells, biopharma revenue, toxic shock syndrome vaccine

This week our guests are Marit Inngjerdingen from the Institute of Clinical Medicine in Norway; Kyle Forcier, senior director of life sciences product marketing at Model N; and Dr. Andreas Roetzer, head of R&D for vaccines at Biomedical Research & Bio-Products. The next breakthrough in cancer treatment? In our body,…

Continue Reading Natural killer cells, biopharma revenue, toxic shock syndrome vaccine

ST7 becomes one of the most common S. aureus clones

Introduction Staphylococcus aureus (S. aureus), a major human opportunistic pathogen, can cause a variety of infectious diseases including skin and soft-tissue infections, bacteremia, ventilator-associated pneumonia and toxic shock syndrome.1,2 A rapid and proper administration of antibiotics is the most important means to inhibit S. aureus’ growth and prevent disease progression….

Continue Reading ST7 becomes one of the most common S. aureus clones

First toxic shock syndrome vaccine phase 2 study completed

The first vaccine to potentially prevent Staphylococcal-induced toxic shock syndrome (TSS) has successfully completed a phase 2 study. TSS is a life-threatening condition caused by toxins that can lead to multiple organ failure and death. Nosocomial pathogen methicillin-resistant Staphylococcus aureus (MRSA) bacteria are resistant to widely-used antibiotics. Infections with MRSA…

Continue Reading First toxic shock syndrome vaccine phase 2 study completed

DNA replication study targets genes for antibiotic resistance

Model of Rep-mediated SaPI DNA initiation of replication. (A) The ATP-independent flexibility of CTD exposes the residues involved in iteron recognition. The diameter of the barrel in its N and C terminal sides might accommodate dsDNA. In (B), two hexamers have been speculatively depicted embracing dsDNA. Potential hexamer-hexamer interactions might…

Continue Reading DNA replication study targets genes for antibiotic resistance

Why The Aridis Pharmaceuticals Stock Dropped 34.96% (ARDS)

The stock price of Aridis Pharmaceuticals (ARDS) fell by 34.96% today. This is why. The stock price of Aridis Pharmaceuticals (ARDS) fell by 34.96% today. This is why. Why: Aridis Pharmaceuticals announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational…

Continue Reading Why The Aridis Pharmaceuticals Stock Dropped 34.96% (ARDS)

Aridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumonia

gorodenkoff Aridis Pharmaceuticals (NASDAQ:ARDS) monoclonal antibody therapy AR-301 failed the main goal in a phase 3 trial to treat Ventilator Associated Pneumonia (VAP) caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). The study, dubbed AR-301-002, evaluated the superiority of adjunctive use of AR-301 with standard of care (SOC) antibiotics versus…

Continue Reading Aridis stock slumps ~25% as antibody drug fails phase 3 trial in pneumonia

Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)

Aridis Pharmaceuticals, Inc. LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics…

Continue Reading Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)

Aridis Pharmaceuticals Inc. (ARDS) Reports Top-Line Results of Phase 3 Trial of AR-301

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. (Updated – January 25, 2023 4:28 PM EST) Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301…

Continue Reading Aridis Pharmaceuticals Inc. (ARDS) Reports Top-Line Results of Phase 3 Trial of AR-301

Destiny Pharma’s XF-73 Nasal in focus as US CDC emphasises need for decolonisation agents

Destiny Pharma (DEST Follow | DEST), a clinical stage biotechnology company, issued a note detailing an increased focus on infection prevention by the US CDC and FDA regulators as well as the medical community at large, following recent announcements and publications in leading medical journals. Destiny released the note as context for…

Continue Reading Destiny Pharma’s XF-73 Nasal in focus as US CDC emphasises need for decolonisation agents

Aridis Reports Top-Line Results of the Phase 3

LOS GATOS, Calif, Jan. 25, 2023 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) today announced top-line results from the AR-301-002 Phase 3 study, which evaluated the superiority of adjunctive use of the investigational monoclonal antibody candidate AR-301 with standard of care (SOC) antibiotics versus SOC antibiotics alone, for the…

Continue Reading Aridis Reports Top-Line Results of the Phase 3

CRISPR/Cas12a-based magnetic relaxation switching biosensor for nucleic acid amplification-free and ultrasensitive detection of methicillin-resistant Staphylococcus aureus

doi: 10.1016/j.bios.2022.114984. Online ahead of print. Affiliations Expand Affiliations 1 College of Food Science and Technology, Huazhong Agricultural University, Wuhan, 430070, Hubei, China. Electronic address: wly2025@163.com. 2 College of Food Science and Technology, Huazhong Agricultural University, Wuhan, 430070, Hubei, China. Electronic address: wzl186@webmail.hzau.edu.cn. 3 School of Food Science and Engineering,…

Continue Reading CRISPR/Cas12a-based magnetic relaxation switching biosensor for nucleic acid amplification-free and ultrasensitive detection of methicillin-resistant Staphylococcus aureus

Development of a novel core genome MLST scheme for tracing multidrug resistant Staphylococcus capitis

Cui, B., Smooker, P. M., Rouch, D. A., Daley, A. J. & Deighton, M. A. Differences between two clinical Staphylococcus capitis subspecies as revealed by biofilm, antibiotic resistance, and pulsed-field gel electrophoresis profiling. J. Clin. Microbiol. 51, 9–14 (2013). CAS  PubMed  PubMed Central  Article  Google Scholar  Tevell, S., Hellmark, B.,…

Continue Reading Development of a novel core genome MLST scheme for tracing multidrug resistant Staphylococcus capitis

P. aeruginosa isolated from patients with aural infections

Introduction Aural infections are one of the most common diseases of the head and neck and are predominantly caused by bacterial infections of the ear canal. Several studies from different countries have reported that Pseudomonas aeruginosa is the most common pathogen isolated from ear canal secretions, followed by Staphylococcus aureus.1…

Continue Reading P. aeruginosa isolated from patients with aural infections

hisat2 alignment showing 0% aligned but sam file is 6GB in size.

hisat2 alignment showing 0% aligned but sam file is 6GB in size. 0 Hello, I am trying to align my fastq files with the reference genome assembly (MRSA ATCC 33591). The sam file formed is some 5-6 GB in size whereas hisat2 output is showing 0.0% alignment rate. I am…

Continue Reading hisat2 alignment showing 0% aligned but sam file is 6GB in size.

How to align fastq files against a reference assembly

How to align fastq files against a reference assembly 0 Hello, I am trying to align fastq files against the bacterial MRSA ATCC 33591 reference genome. The problem I am facing is that I have the reference assembly in fasta format with multiple sequences and upon creating index with hisat2-build…

Continue Reading How to align fastq files against a reference assembly